Cebranopadol
Cebranopadol
$10,000.00
Cebranopadol is a novel small molecule analgesic, which was discovered by Grünenthal. Cebranopadol represents a novel, first-in-class potent analgesic that has a dual mechanism of action as a potent agonist of both the nociceptin/orphanin FQ peptide receptor (NOP) and opioid peptide receptor.
Author: Sultan Khan
Publisher: Datamonitor Healthcare
- Description
- Companies
- Contents
Drug Overview
Cebranopadol is a novel small molecule analgesic, which was discovered by Grünenthal. Cebranopadol represents a novel, first-in-class potent analgesic that has a dual mechanism of action as a potent agonist of both the nociceptin/orphanin FQ peptide receptor (NOP) and opioid peptide receptor. This difference in mechanism of action has several advantages. In animal models, cebranopadol demonstrated greater potency for neuropathic pain versus acute pain compared to selective MOP receptor agonist. Additionally, in animal models, NOP receptor agonists demonstrate comparably lower opioid-related side effects, such as respiratory depression.
CONTENTS
4 OVERVIEW
4 Drug Overview
5 Product Profiles
5 cebranopadol : Neuropathic pain
LIST OF FIGURES
9 Figure 1: Cebranopadol for neuropathic pain – SWOT analysis
10 Figure 2: Datamonitor Healthcare’s drug assessment summary of cebranopadol for neuropathic pain
11 Figure 3: Datamonitor Healthcare’s drug assessment summary of cebranopadol for neuropathic pain
13 Figure 4: Cebranopadol sales for neuropathic pain across the five major EU markets, by country, 2017–26
LIST OF TABLES
6 Table 1: Cebranopadol drug profile
7 Table 2: Cebranopadol Phase II data in neuropathic pain
14 Table 3: Cebranopadol sales for neuropathic pain across the five major EU markets, by country ($m), 2017–26
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the